ALD Clinical Trials

2 recruiting

ALD Trials at a Glance

101 actively recruiting trials for ald are listed on ClinicalTrialsFinder across 6 cities in 34 countries. The largest study group is Not Applicable with 23 trials, with the heaviest enrollment activity in Boston, Chongqing, and Chengdu. Lead sponsors running ald studies include Qifu Li, Centre Hospitalier Universitaire, Amiens, and Xinjiang Medical University.

Browse ald trials by phase

Treatments under study

About ALD Clinical Trials

Looking for clinical trials for ALD? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new ALD trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about ALD clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 101 trials

Recruiting

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

Small Lymphocytic LymphomaWaldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma+2 more
National Heart, Lung, and Blood Institute (NHLBI)1,000 enrolled1 locationNCT00923507
Recruiting
Phase 2

A Phase II Clinical Study on the Efficacy and Safety of HRS-1780 in Participants With Primary Aldosteronism

Primary Aldosteronism
Shandong Suncadia Medicine Co., Ltd.60 enrolled2 locationsNCT07470983
Recruiting

Study on the Incidence of Adrenal Insufficiency After Surgery in Primary Aldosteronism Patients Concurrent With or Without Autonomous Cortisol Secretion

Primary AldosteronismAdrenal InsufficiencyAutonomous Cortisol Secretion
Qifu Li521 enrolled1 locationNCT06955286
Recruiting

Steroids-Based Screening for Primary Aldosteronism

HypertensionPrimary Aldosteronism
Qifu Li406 enrolled1 locationNCT06941116
Recruiting
Phase 1Phase 2

A Dose-Escalation and Expansion Study of BGB-16673 in Participants With B-Cell Malignancies

Diffuse Large B Cell LymphomaChronic Lymphocytic LeukemiaNon-Hodgkin Lymphoma+6 more
BeOne Medicines614 enrolled127 locationsNCT05006716
Recruiting

Observational Study of Cardiac Arrhythmias During Treatment With BTK Inhibitors or Venetoclax

Mantle Cell LymphomaSudden Cardiac DeathChronic Lymphocytic Leukemia (CLL)+3 more
National Heart, Lung, and Blood Institute (NHLBI)135 enrolled1 locationNCT05724121
Recruiting
Phase 3

A Study to Assess Efficacy and Safety of Baxdrostat in Participants With Primary Aldosteronism

Primary Hyperaldosteronism
AstraZeneca250 enrolled89 locationsNCT07007793
Recruiting
Phase 1Phase 2

Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-Degrader

Non-Hodgkin LymphomaMantle Cell LymphomaFollicular Lymphoma+6 more
BeiGene146 enrolled29 locationsNCT05294731
Recruiting
Phase 2

Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)

Hematologic MalignanciesWaldenstroms MacroglobulinaemiaNon-Hodgkins Lymphoma+1 more
Merck Sharp & Dohme LLC490 enrolled121 locationsNCT04728893
Recruiting
Phase 2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
National Cancer Institute (NCI)92 enrolled125 locationsNCT04840602
Recruiting
Phase 2

Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)

Waldenstrom MacroglobulinemiaLymphoplasmacytic Lymphoma
AbbVie14 enrolled7 locationsNCT07387471
Recruiting
Phase 2Phase 3

PRECISION-BP: Precision Chronopharamacotherapy Targeting NP-RAAS-BP Rhythm Axis

ObesityCardiovascular DiseasesHypertension+3 more
University of Alabama at Birmingham160 enrolled1 locationNCT04971720
Recruiting

Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS)

Heart FailurePainInsomnia+22 more
Duke University5,000 enrolled51 locationsNCT04278404
Recruiting
Phase 2

Zanubrutinib, Bendamustine, Rituximab Prev. Untreated WM

Waldenstrom Macroglobulinemia
Massachusetts General Hospital55 enrolled5 locationsNCT06561347
Recruiting
Phase 1

A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies

Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Waldenstrom Macroglobulinemia (WM)+2 more
Nurix Therapeutics, Inc.248 enrolled16 locationsNCT04830137
Recruiting
Not Applicable

REnin-guided TherApy With MinEralocorticoid Receptor Antagonists in Primary Aldosteronism - Feasibility Study

Primary Aldosteronism
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal58 enrolled1 locationNCT06108427
Recruiting
Phase 2

Epcoritamab in Previously Treated WM

Waldenstrom MacroglobulinemiaB-Cell Lymphoproliferative Disorder
Gottfried von Keudell, MD PhD20 enrolled3 locationsNCT06510491
Recruiting
Not Applicable

Phenotypic and Functional Study of Bone Marrow Mesenchymal Stem Cells in Waldenström Macroglobulinemia

Waldenström Macroglobuloinemia
Centre Hospitalier Universitaire, Amiens50 enrolled1 locationNCT07471074
Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia
BeiGene111 enrolled8 locationsNCT05640102
Recruiting
Phase 1Phase 2

Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma

DLBCL - Diffuse Large B Cell LymphomaLymphomaLymphoplasmacytic Lymphoma+4 more
ModeX Therapeutics, An OPKO Health Company180 enrolled1 locationNCT07249905